FreeCME
LoginRegister Logout My Profile My Courses

New Directions Targeting Inflammatory and Fibrotic Pathways in the Management of SSc-ILD

CME: 1.0

July 29, 2021
No Comments
/ Print / Reprints /
| Share More
/ Text Size+
Larger Smaller
[X]

Related Articles

Rapid-Fire Roundtable on Melanoma: Focus on Advances in Adjuvant Treatment, Neoadjuvant Treatment, and Management of Metastatic Disease

Interpretation of ECHO and the Path to Diagnostic Certainty in PAH

Patients with SSc may develop ILD early in the disease and SSc should be considered in some cases of ILD. There are new agents to treat inflammation and fibrosis in SSc-ILD.

Source: https://learning.freecme.com/a/37783P3cw4sN

Post a comment to this article